menu
    • menu

    Company profile for NanoViricides

    NEW Drugs in Dev: 5
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    NanoViricides, Inc. is a global leader in the development of nanomedicine drugs against viruses. Our unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against viruses. A nanoviricide is designed to specifically attack enveloped virus particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immun...
    NanoViricides, Inc. is a global leader in the development of nanomedicine drugs against viruses. Our unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against viruses. A nanoviricide is designed to specifically attack enveloped virus particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immunotherapeutics do. A nanoviricide can also be designed to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    NanoViricidesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Controls Drive, Shelton, CT 06484
    Telephone
    Telephone
    +1-203-937-6137
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.nanoviricides.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NanoViricides: NV-387 a Strong Candidate for Ebola Emergency
    NanoViricides: NV-387 a Strong Candidate for Ebola Emergency

    18 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-18/ebola-global-health-emergency-needs-a-broad-spectrum-drug-nv-387-is-a-strong-potential-candidate

    PHARMIWEB
    18 May 2026
    Share Share
    US FDA Grants Orphan Drug Designation To NV-387 For Measles
    US FDA Grants Orphan Drug Designation To NV-387 For Measles

    04 May 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-05-04/nv-387-for-the-treatment-of-measles-is-granted-orphan-drug-designation-by-the-us-fda

    PHARMIWEB
    04 May 2026
    Share Share
    Measles Rare Pediatric Disease Drug Designation Filed for NV-387
    Measles Rare Pediatric Disease Drug Designation Filed for NV-387

    07 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-07/measles-rare-pediatric-disease-drug-designation-application-filed-for-nv-387-prv-provides-for-stron

    PHARMIWEB
    07 Apr 2026
    Share Share
    Ph II Clinical Trial of Monkeypox Treatment by NV-387 to Commence
    Ph II Clinical Trial of Monkeypox Treatment by NV-387 to Commence

    01 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-01/phase-ii-clinical-trial-of-monkeypox-treatment-by-nv-387-to-commence-soon-announces-nanoviricides

    PHARMIWEB
    01 Apr 2026
    Share Share
    NanoViricides Wraps Phase II NV-387 Gummies, Presents at NIBA
    NanoViricides Wraps Phase II NV-387 Gummies, Presents at NIBA

    11 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-11/nanoviricides-presenting-at-nibas-152nd-investment-conference-in-fort-lauderdale-fl-march-12-2026

    PHARMIWEB
    11 Mar 2026
    Share Share
    MPox Orphan Drug Designation Application Filed for NV-387
    MPox Orphan Drug Designation Application Filed for NV-387

    12 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-12/mpox-orphan-drug-designation-application-filed-for-nv-387-declares-nanoviricides

    PHARMIWEB
    12 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search